Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 1, 2000, Pages 336-344

  Brown, Nancy J ^a,b   Kim, Kyung Soo ^a,b   Chen, Yan Qun ^b   Blevins, Lewis S ^a   Nadeau, John H ^a   Meranze, Steven G ^a   Vaughan, Douglas E ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CORTICOSTEROID; DEXAMETHASONE; LUCIFERASE; MINERALOCORTICOID; PLASMINOGEN ACTIVATOR INHIBITOR; SPIRONOLACTONE;

ANIMAL CELL; AORTA MEDIA; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; ENZYME ACTIVITY; FIBRINOLYSIS; HORMONE ACTION; HUMAN; HUMAN CELL; HYPERALDOSTERONISM; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPORTER GENE;

ADRENAL CORTEX HORMONES; ADRENAL GLANDS; ALDOSTERONE; ANGIOTENSIN II; ANIMALS; BLOTTING, NORTHERN; CELLS, CULTURED; CHROMOSOME MAPPING; DEXAMETHASONE; GENES, REPORTER; HUMANS; HYDROCORTISONE; HYPERALDOSTERONISM; MUSCLE, SMOOTH, VASCULAR; MUTAGENESIS, SITE-DIRECTED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; TISSUE PLASMINOGEN ACTIVATOR; TRANSFECTION;

ANIMALIA;

EID: 0034457808     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.1.336     Document Type: Article

References (56)

1. Essential hypertension: Renin and aldosterone, heart attack and stroke
2. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
3. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
4. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
5. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 m cultured endothelial cells
6. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
7. Cell-associated plasminogen activation: Regulation and physiologic functions
8. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
9. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls
10. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
11. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
12. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm
13. Proteinases and extracellular matrix remodeling
14. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
15. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II
16. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans
17. Effect of trandolapril and losartan on plasma PAI-1 and fibrinogen in hypertensive post-menopausal women
18. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
19. Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter
20. Regulation of plasminogen activator inhibitor-1 levels in human monocytes
21. Glucocorticoid and cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor gene expression in primary cultures of rat hepatocytes
22. Human fibroblasts produce inhibitor directed against plasminogen activator when treated with glucocorticoids
23. Plasminogen activator inhibitor type I biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells
24. Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231
25. The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to an inhibitor produced y bovine aortic endothelial cells
26. Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells
27. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control
28. Culture of vascular endothelium
29. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose m vascular smooth muscle cells
30. Multiple enhancer elements mediate reduction of c-fos in vascular smooth muscle cells
31. Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects
32. Potentiation of angiotensin II action by corticosteroids in vascular tissue
33. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses
34. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells
35. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor
36. Mechanisms of action of mineralocorticoid hormones
37. Localization of 2β-OH steroid dehydrogenase isoforms in aortic endothelial cells
38. Substrate and inhibitor specificity of the cloned human 11β-hydroxysteroid dehydrogenase type 2 isoform
39. 2+ in vascular smooth muscle cells
40. Angiotensin II and angiotensin IV induce PAId expression through a shared promoter element
41. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis
42. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states
43. Evidence for a renin receptor on human mesangial cells: Effects on PAI-1 and cGMP
44. Fibrinolytic response during exercise and epinephrine infusion in the same subjects
45. Physical exertion Induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis
46. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis
47. Prevention of aortic fibrosis by pironolactone in spontaneously hypertensive rats
48. Role of aldosterone in the remnant kidney model in the rat
49. Vasodilation to acetylcholine in primary and secondary forms of human hypertension
50. Aldosterone biosynthesis and action in vascular cells
51. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans
52. PAI-1, obesity, insulin resistance and risk of cardiovascular events
53. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
54. The effect of spironolactone on morbidity and mortality in patients with severe heart failure